Skip to main content
. 2021 Apr 1;42(13):1216–1227. doi: 10.1093/eurheartj/ehab094

graphic file with name ehab094f6.jpg

Dapagliflozin prolonged survival irrespective of baseline patient characteristics, largely driven by reductions in non-CV death.